The podcast discusses the rising incidence and mortality rates of endometrial cancer in the United States, particularly among Black women. The key factors contributing to this trend include the increasing prevalence of obesity, the aging population, and the decrease in elective hysterectomies.
When treating patients with advanced or recurrent endometrial cancer, the speaker emphasizes the importance of understanding the tumor's molecular characteristics, such as mismatch repair (MMR) status and HER2 expression. For patients with MMR-deficient tumors, the addition of PD-1 inhibitors (dostarlimab or pembrolizumab) to standard chemotherapy has shown significant improvements in progression-free survival. For patients with HER2-amplified tumors, the addition of HER2-targeted therapies (trastuzumab or trastuzumab-pertuzumab) to chemotherapy is also a promising approach.
The podcast also explores the role of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan, which have demonstrated impressive activity in HER2-expressing endometrial cancers. Additionally, the speaker discusses the potential of targeting replication stress and cell cycle checkpoints, particularly with WEE1 inhibitors, in high-grade endometrial cancers.
The use of PARP inhibitors in endometrial cancer is also discussed, highlighting the need for further research to identify the appropriate patient population that may benefit from this therapy. The podcast concludes by mentioning other emerging therapies, such as hormonal therapies and cellular therapies, that hold promise for improving outcomes in endometrial cancer.
To Another Language
from source content
www.medscape.com
Thông tin chi tiết chính được chắt lọc từ
by Ursula A. Ma... lúc www.medscape.com 07-24-2024
https://www.medscape.com/viewarticle/999850Yêu cầu sâu hơn